September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma with Vitreous Seeding
Author Affiliations & Notes
  • Matthew Karl
    Ophthalmology, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Jasmine Francis
    Ophthalmology, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Saipriya Iyer
    Ophthalmology, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Brian P Marr
    Ophthalmology, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • David H Abramson
    Ophthalmology, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   Matthew Karl, None; Jasmine Francis, None; Saipriya Iyer, None; Brian Marr, Aura Biosciences (C); David Abramson, None
  • Footnotes
    Support  Fund for Ophthalmic Knowledge, Inc.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3687. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Matthew Karl, Jasmine Francis, Saipriya Iyer, Brian P Marr, David H Abramson; Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma with Vitreous Seeding. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3687.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the impact of intravitreal chemotherapy on intraocular pressure in children with retinoblastoma.

Methods : Retrospective study of ten eyes of ten retinoblastoma patients (7 males, 3 females, mean age 33.6 ± 9.4 months) with vitreous seeding injected with intravitreal melphalan and topotecan. Intraocular pressure (IOP) was measured with Tonopen at baseline prior to injecting and then repeatedly following each intravitreal injection.

Results : Mean pre-injection IOP was 8.2 ± 2.3 mm Hg (range 4.0 – 12.0 mm Hg). Mean IOP 1-30 seconds after intravitreal melphalan (first injection) was 45.4 ± 14.3 mm Hg. 89.5% of patients declined to ≤ 29 mm Hg in a mean 153.3 ± 97.5 seconds. Mean IOP 1-30 seconds after intravitreal topotecan (second injection) was 44.5 ± 11.0 mm Hg and decreased to 31.0 ± 5.0 by 150 seconds after injection. No significant relationship was found between age and post-injection IOP elevation. IOP exceeded calculated mean arterial perfusion pressure in four encounters.

Conclusions : Intravitreal chemotherapy caused a transient rise in IOP. Post-injection IOP elevations can reach levels that may exceed mean arterial pressure.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×